2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1785

A Data-Driven Approach to Guide Physicians When Considering the Differential Diagnosis of IgG4-Related Disease
Abstract Number: 1786

Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives
Abstract Number: 1787

How to Better Diagnose IgG4 Related Disease: a Single-Center Based Experience
Abstract Number: 1788

Predictive Factors for Work-Day Loss in a Multi-Center Study in Behcet’s Disease: Indirect Costs for Healthcare
Abstract Number: 1789

Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey
Abstract Number: 1790

An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
Abstract Number: 1791

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Abstract Number: 1792

Work Productivity Is Impaired in Patients with Behcet’s Syndrome
Abstract Number: 1793

The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome
Abstract Number: 1794

Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
Abstract Number: 1795

New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
Abstract Number: 1796

Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
Abstract Number: 1797

An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
Abstract Number: 1798

Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
Abstract Number: 1799

Increased Vein Wall Thickness in Behçet’s Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].